AstraZeneca PLC (ADR) (NYSE:AZN) Rating Increased
In an analyst note revealed on Monday morning, equity analysts at JP Morgan’s equities research division boosted Astrazeneca Plc (ADR) (NYSE:AZN)’s stock from Neutral to Overweight.
The firm’s rating upgrade is well-received by stock traders, as NYSE:AZN is right now trading 0.06% higher at $33.84 as of 7:59 AM New York time. AstraZeneca PLC (ADR)’s stock is 0% over the last 200 days. It has underperformed the S&P 500 Index, which has surged 6.00% over the same time period.
According to data compiled by Thomson Reuters, AstraZeneca PLC (ADR) (NYSE:AZN)’s stock is covered by 4 equity analysts across the Street, with 0 analysts giving it a Sell rating, 1 a Buy rating, while 3 consider it a Hold. The 12-month consensus target price for the stock is $35.41, which reflects an upside potential of 4.64% over the current price.
AstraZeneca PLC (ADR) (NYSE:AZN) Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
AstraZeneca PLC (ADR) (NYSE:AZN) traded up 0.06% on 1 January, hitting $33.84. A total of 955,937 shares of the company’s stock traded hands. This is down from average of 3.15 million shares. AstraZeneca PLC (ADR) has a 52 week low of $25.55 and a 52 week high of $35.6. The company has a market cap of $83.94 billion and a P/E ratio of 24.2.
Get the latest AstraZeneca PLC (ADR) (NYSE:AZN) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
The post AstraZeneca PLC (ADR) (NYSE:AZN) Wins Overweight Rating for Neutral from JP Morgan appeared first on Octafinance.